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Abstract
Developing new vaccination strategies and optimizing current vaccines through heterologous prime-boost carries
the promise of integrating the benefits of different yet synergistic vectors. It has been widely thought that the
increased immunity afforded by heterologous prime-boost vaccination is mainly due to the minimization of
immune responses to the carrier vectors, which allows a progressive build up of immunity against defined epi-
topes and the subsequent induction of broader immune responses against pathogens. Focusing on CD8
+ T cells,
we put forward a different yet complementary hypothesis based primarily on the systematic analysis of DNA vac-
cines as priming agents. This hypothesis relies on the finding that during the initiation of immune response, acqui-
sition of co-inhibitory receptors such as programmed cell death-1 (PD-1) is determined by the pattern of antigen
exposure in conjunction with Toll-like receptor (TLR)-dependent stimulation, critically affecting the magnitude and
profile of secondary immunity. This hypothesis, based upon the acquisition and co-regulation of pivotal inhibitory
receptors by CD8
+ T cells, offers a rationale for gene-based immunization as an effective priming strategy and, in
addition, outlines a new dimension to immune homeostasis during immune reaction to pathogens. Finally, this
model implies that new and optimized immunization approaches for cancer and certain viral infections must
induce highly efficacious T cells, refractory to a broad range of immune-inhibiting mechanisms, rather than solely
or primarily focusing on the generation of large pools of vaccine-specific lymphocytes.
The ‘magic’ of heterologous prime-boost
vaccination
Vaccines are arguably the best medical tools we have
at our disposal to fight widespread infectious diseases.
Despite decades of vaccine research and development
against life-threatening infectious diseases with global
impact [1], culminating with the recent licensing of
vaccines against human papillomaviruses (HPV) [2], a
key cause of cervical cancer, successes have been con-
fined primarily to prophylaxis. Vaccination has also
been extensively researched for the prevention of HIV
infection. Therapeutic immunization for cancer or
chronic viral infection, however, brings in a new set
of lessons and challenges with a few successes to date,
such as treatment of HPV-related lesions [3]. It
became rapidly evident that the conventional paradigm
of eliciting, amplifying, and maintaining immune
responses with conventional vectors and homologous
prime-boost approaches fell short of expectations in
the clinic due to suboptimal immune response results.
Two decades since the first cloning of tumor antigens
[4], multiple vaccines are currently in development.
Thus far, however, sipuleucel T (Provenge®) is the only
approved therapeutic cancer vaccine in the US to date,
consisting of autologous DCs expressing prostate acid
phosphatase (PAP) and producing granulocyte macro-
phage colony-stimulating factor (GM-CSF) to treat
hormone-refractory prostate cancer [5].
The HIV vaccine field has unquestionably been at the
forefront of vaccine research, exploring potent immuni-
zation strategies comprised of synthetic vectors rather
than cell-based vaccines. This is in contrast to efforts in
cancer vaccine development where cell-based vaccines
currently lead the field, while many synthetic and viral
vector approaches are in clinical development [6,7].
Nevertheless, homologous prime-boost approaches for
the prophylaxis of HIV, such as the Vaxgene program,
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While in parallel, emerging evidence over the last two
decades showed that novel prime-boost protocols inte-
grating different vectors such as recombinant viruses
and proteins [9,10] did yield considerably higher
immune responses with protective capability in several
animal models. With the advent of other vectors such as
DNA vaccines, and a range of recombinant microbial
vectors including alpha virus replicons, research in the
area of heterologous prime-boost vaccination against
HIV has expanded and resulted in hundreds of preclini-
cal and clinical studies. Interestingly, the most promis-
ing clinical regimens to date include: i) the RV144
landmark HIV ‘Thai trial’ which utilized recombinant
viral priming followed by a protein boost and was the
first to show modest yet statistically significant evidence
of HIV vaccine efficacy in man [10]; ii) DNA priming
coupled with protein [11]; or iii) DNA priming followed
by a recombinant virus boost [12].
Significant evidence points to two major reasons why
heterologous prime-boost vaccination is a more promis-
ing strategy compared to homologous prime-boosting: i)
diminished anti-vector antibody responses [13] known
to interfere with immunity against target epitopes
through the clearance and degradation of vaccine via
vaccine-antibody immune complexes; and ii) there is the
potential for different vectors to work synergistically by
inducing complementary arms of the immune response
to jointly control complex pathogenic processes and
overcome immune escape mechanisms. For example,
while recombinant proteins are quite effective at indu-
cing B and Th immunity, viral vectors can be more
effective at inducing cytotoxic T cells [14].
DNA vaccine vectors offer several advantages, including
the potential to elicit MHC class I-restricted immunity,
reduced induction of anti-vector antibody responses, and
reliance on a simple manufacturing process [15]. Never-
theless, DNA vaccination alone has yielded disappointing
results in numerous clinical trials due to modest immune
responses [16]. These results were largely attributed to
low levels of vector-encoded antigen, resulting in low
numbers of APCs expressing target epitopes, and subse-
quent inferior T cell stimulation and expansion in vivo
[17]. Furthermore, intra-dermal gene-gun delivery [18],
intra-lymphatic administration [19,20], or other enhan-
cing approaches such as electroporation [21], have only
partially improved the immune response achievable by
DNA vaccination alone. Nevertheless, the potential of
immune priming without the generation of interfering
anti-vector antibodies has positioned DNA vaccines (Fig-
ure 1) as a primary component of several heterologous
prime-boost vaccines in development for the treatment of
diseases such as HIV, other microbes and cancer
[11,22-37]. In addition, such protocols offer a more
practical alternative for active immunotherapy of cancer
and other diseases since they rely on synthetic or ‘off the
shelf’ vectors, as compared to personalized DC-based
vaccines [38].
The optimal positioning of current and future DNA
vectors within innovative heterologous prime-boost
immunization regimens requires a deeper understanding
of the mechanism of action of DNA vaccination. A key
observation from many studies to date is that interchan-
ging the order of vectors utilized in these regimens has
a dramatic impact on the resulting immune response.
For example, while DNA priming followed by a virus
boost resulted in significant epitope-specific responses,
viral priming followed by DNA boost failed to reproduce
this level of specific immunity [39]. A similar result was
observed with other vectors in a distinct model, clearly
supporting a precise sequence of administration of vec-
tors as a major factor determining the magnitude of
immunity [40], although this hypothesis still requires
f u r t h e rt e s t i n gi no t h e rh e t erologous prime-boost vac-
cine protocols. This asymmetry between priming and
boosting vectors could very well be at the heart of both
the mechanism and advantage of heterologous prime-
boost regimens. Therefore, the remainder of this review
will focus on this key feature and its underlying
mechanism, with emphasis on DNA vaccines as priming
agents and CD8
+ T cell immunity as the desired out-
come, as it pertains to the control of cancer and chronic
viral infections. Moreover, although we focus on the
functionality of CD8
+ T cells in this review, we recog-
nize the importance of CD4
+ T cells and the possibility
that these cells may influence the outcome of vaccine
protocols with respect to PD-1 expression by CD8
+
T cells.
PD-1 and co-inhibitory receptors: a new
dimension to prime-boosting and immune
regulation
The fundamental concept behind heterologous prime-
boost vaccination is the synergistic contribution of two
categories of vectors to induce enhanced immunity
against given epitopes. To investigate the immune
mechanisms underlying this process, we initiated a sys-
tematic evaluation utilizing a reductionist approach that
encompasses simple vectors with well-defined MHC
class I-restricted epitopes. Using a Melan A/MART-1
preclinical experimental model, we developed a strategy
that greatly enhances the immune properties of non-
replicating vectors and biological response modifiers by
direct intra-nodal administration of plasmid and peptide
[19,41]. We showed that the sequence and the route of
administration of plasmid and peptide were absolutely
essential to achieve improved antigen-specific CD8
+
T cell immune responses [40]. While intra-lymph node
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afforded a robust expansion of epitope-specific CD8
+
T cells (on the order of 1/2 - 1/10 specific T cells/total
CD8
+ T cells), reversing the order of the vectors resulted
in a limited overall T cell expansion (~1/100 - 1/1000 or
less, of specific T cells/total CD8
+ T cells) within the
same range of homologous prime-boost vaccination [40].
A closer look at the immunity primed by plasmid showed
that, in stark contrast to peptide priming, the epitope-
specific CD8
+ T cells, although few in numbers (~1/100
specific/total CD8
+ T cells), had some strikingly distin-
guishing features. Within the population of CD8
+ T cells
initiated by plasmid, we found a significant frequency of
the lymphatic migration marker CD62L
+ (central/lym-
phoid-memory) epitope-specific CD8
+ T cells with a lim-
ited capability to produce proinflammatory cytokines
upon peptide stimulation ex vivo. Nevertheless, these
DNA vaccine-primed cells showed long-term persistence
in vivo and displayed a high expansion potential following
in vivo or in vitro re-exposure to antigen, associated with
a rapid loss of CD62L and a broadening of their func-
tional capabilities [40].
This obviously raised the question: Does priming with
a DNA vaccine result in CD8
+ T cells that are more
resilient to negative regulatory mechanisms that would
otherwise impose restrictions on the expansion and
activity of this key subset of T cells? To test our
hypothesis, we compared the global gene expression in
epitope-specific CD8
+ T cells generated by vaccination
against Melan A/MART-1 with plasmid versus peptide
in mouse [42]. We found numerous differences in
regards to the transcriptome, most notably at the level
of expression of genes encoding inhibitory receptors
(Figure 2). More specifically, PD-1, CTLA-4, Lag-3 and
the prostaglandin receptor Ptger2 were all significantly
up-regulated in antigen-specific CD8
+ T cells from pep-
tide (but not DNA) immunized mice, with the latter
retaining a more ‘naïve-like’ phenotype from this point
of view. In contrast, a member of the Klr family con-
trolling the natural killer activity of lymphocytes was
vastly down-regulated in CD8
+ T cells primed with pep-
tide. Previous evidence also suggested that DNA vacci-
nation elicited specific T cells with low PD-1 expression
levels [43,44].
Boosting vectors Results summary References
Vector 
category
Targets / Formulations
Polypeptides 
or recombinant 
proteins
Env of primary HIVs (subtypes A-E)
Hsp65-Gastrin releasing peptide
Melan A  peptide
Induction of neutralizing antibodies in rabbit
Antibody and anti-tumor effect in mouse
Induction of elevated T cell response
(22)
(23)
(40)
Microbial 
vectors
Live influenza virus 
BCG
Vaccinia (MVA) expressing HIV antigens
Fowlpox – expressing HIV antigens
Adenovirus – expressing HIV antigens
Adenovirus – expressing α-fetoprotein
VSV – expressing Gag of HIV
Induction of robust CTL immunity in mouse
Immunity against Hsp67, 70, Apa in calves
Protective immunity against SHIV in primates
Protective immunity against SHIV in primates
Protective immunity against SHIV in primates
Protective Th1 immunity in a mouse tumor model
Enhanced immunogenicity in primates
(24)
(25)
(26)
(27) 
(28)
(29)
(30)
Inactivated 
viruses 
Inactivated rabies
Inactivated influenza
Increased neutralizing immunity in mice, cattle
Increased neutralizing antibody levels in mouse
(31)
(32)
1A. Preclinical models
1B. Clinical trials
Boosting vectors Results summary References
Vector category Targets / Formulations
Proteins Polyvalent HIV Env formulation* Multivalent humoral and polyfunctional cellular 
immunity in healthy volunteers 
(11, 33)
Microbial vectors Vaccinia (NYVAC) – HIV
Adenovirus expressing PSMA
Vaccinia (MVA) – melanoma epitopes
Vaccinia (MVA) – malaria TRAP
Increased cellular immunity in healthy volunteers
Antibodies elicited in prostate carcinoma patients
Immunity and some clinical response in patients
T cell response and partial protection 
(34)
(35)
(36)
(37)
* DNA priming against Gag and multiple envelope proteins.
In blue: studies with cancer antigens.   
Figure 1 Representative studies to date, evaluating DNA priming - heterologous boosting.
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[45-47] raised the possibility that this phenomenon,
consisting of the generation of specific T cells that fail
to up-regulate PD-1, extends beyond DNA vaccination.
We investigated this concept by utilizing the opportu-
nity afforded by intra-lymph node administration to
evaluate the immune profile of peptide epitopes and
biological response modifiers in their simplest form.
Intriguingly, a rather low dose of peptide co-adminis-
tered with robust doses of CpG (TLR9 ligand) resulted
in Melan A/MART-1-specific CD8
+ T cells with low
PD-1 expression levels [48], reproducing essentially the
profile achieved by DNA vaccination (Figure 2). In
stark contrast, a peptide dose increase or CpG dose
reduction yielded increased levels of PD-1 expression
on specific CD8
+ T cells. The induction of T cells with
a high PD-1 expression level by peptide immunization
alone may be due to co-presentation by professional
and non-professional APCs alike. Co-administration of
TLR ligands (such as CpG motifs and others) are
expected to activate of APCs resulting in a favorable
PD-1 profile [49-51]. As far as we know, the molecular
mechanisms for these findings remain to be elucidated.
Complementing these results, ex vivo antigen restimu-
lation with simultaneous anti-PD-1 blockade restored
the proliferation of PD-1
high CD8
+ T cells isolated
from mice immunized with peptide only to levels simi-
lar to that of T cells from mice immunized with pep-
tide + CpG or plasmid alone (Figure 3). This result
strongly supports the functional relevance of this co-
inhibitory molecule as a major regulator of CD8
+
T cell activity in the context of DNA priming- hetero-
logous boosting and beyond. Furthermore, this nicely
complements previous observations obtained with
OVA-specific CD8
+ T cells defective in PD-1 expres-
sion in an autoimmune setting, showing the pivotal
negative regulatory role of PD-1 both at the level of
T cell expansion as well as during in situ activity [52].
Summary of transcriptome analysis by gene array applied to Melan A / MART-1 epitope 
specific CD8+ T cells
Gene Symbol Fold change 
(DNA-primed  vs control)
Fold change 
(Peptide-primed vs control)
Klra, lectin subfamily A -2.27 -10.89
Cd160 1.08 -2.34
Lag3 1.41 3.36
Ctla4  -1.66 5.43
Pdcd1 (PD-1) 1.88 7.82
Ptger2 1.09 7.06
Separation of
epitope-specific
CD8+ T cells
Gene array
analysis
Vaccination
Figure 2 Differential co-expression of inhibitory receptors by CD8
+ T cells depending on priming. In brief, epitope-specific T cells from
immunized mice were highly purified and analyzed without additional stimulation. Gene expression patterns were defined using hierarchical
clustering; CD8
+ T cells from naïve mice were used as a reference control. The bottom half of the figure summarizes the results pertaining to
expression of inhibitory receptors such as PD-1, as average fold change of gene expression relative to control. There was coordinated up-
regulation of gene expression corresponding to membrane receptors with inhibitory activity (yellow shaded section: Lag3, CTLA-4 and PD-1) in
CD8
+ T cells primed by peptide without adjuvant, but not DNA vaccine (summary of results in ref. [42]).
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-/- OVA-specific
T cells were adoptively transferred into transgenic
mice expressing the antigen under the rat insulin pro-
moter. The PD-1
-/- T cells proliferated to a higher
extent in draining lymph nodes and caused insulitis
and diabetes, in dramatic contrast to wild-type PD-1-
competent T cells which were unable to mediate a
similar outcome.
With regard to the basic mechanisms of DNA prim-
ing/heterologous boosting, the following model thus
emerges (Figure 4). Effective priming agents such as
DNA vaccines induce a population of antigen-specific
T cells with a central-memory phenotype (CD62L
+)t h a t
reside within lymphoid organs and manifest a reduced
expression of inhibitory receptors such as PD-1, CTLA-
4 and LAG-3, rendering them relatively impervious to a
range of negative regulatory mechanisms. In addition,
they exhibit a subtle cytokine expression potential and
yet have a great capacity for persistence, expansion and
differentiation. Boosting agents such as peptides, if deliv-
ered to achieve optimal exposure and TCR-dependent
stimulation, can then rapidly drive the expansion and
differentiation of DNA-primed CD8
+ T cells to
peripheral memory/effector cells (CD62L
neg)t h a ta r en o
longer confined to the lymphatic system and are able to
survey peripheral organs. These differentiated cells,
nevertheless, simultaneously acquire expression of inhi-
bitory receptors such as PD-1 and are therefore far
more susceptible to negative regulatory mechanisms
in vivo. While boosting would effectively result in acti-
vated cells endowed with potent effector capabilities yet
prone to exhaustion due to high PD-1 expression, itera-
tive priming would lead to a continuous replenishment
of central memory T cells with a low PD-1 expression
level and potentiate a renewed source of effector cells
upon subsequent boosting. It is also quite possible that
co-administration of TLR-ligands with boosting peptide
would limit the acquisition and expression levels of
PD-1 on effector T cells, thus resulting in a prolonged
cellular life-span and enhanced function. This model
attempts to explain the synergy between priming
and boosting vectors at a single epitope level and the
dynamic interplay between various pivotal populations
of antigen-specific T cells (such as central and periph-
eral memory, PD-1
low and PD-1
high)t h a td e t e r m i n e s
the overall immunity against the intended target (Figure
4B). Furthermore, it provides a rationale for why a pre-
cise sequence of administration of different vectors for
priming or boosting the immune response is a crucial
pre-requisite for an enhanced specific T cell response,
measured systemically (Figure 4B) or within lymphoid
organs (Figure 5).
The finding that the low PD-1 expression profile
afforded by DNA vaccination could be reproduced by
intra-lymph node immunization with limited amounts
of peptide and TLR stimulation sheds light on the
mechanism of action of DNA vaccines and their potency
as priming agents in terms of: i) the importance of
extended yet reduced levels of antigen exposure; and ii)
a role for TCR-independent stimulation through TLRs.
However, it should be noted that within this model (Fig-
ure 4 and 5) DNA vaccines alone have a limited capabil-
ity to elicit robust immune responses in homologous
prime-boost regimens, as supported by experimental
clinical observations as well as mechanistic studies
[15-17]. Instead, we argue that the use of DNA vaccines
for the purpose of priming high quality antigen-specific
CD8
+ T cell responses is a viable and highly promising
strategy. For example, one could envisage alternating
the administration of a DNA vaccine with other vectors
such as peptides, recombinant proteins, or viruses for
the purpose of inducing and periodically replenishing
low PD-1-expressing central-memory T cells and then,
through boosting, maintaining a pool of highly func-
tional effector cells. Thus, such heterologous prime-
boost regimens would ensure the presence of desirable
T cell populations over a longer interval, prevent overall
PD-1 blockade restores the proliferation of PD-1hi CD8+ T cells
Source of CD8+ T cells
(Immunization)
Proliferation during antigen-recall
Treatment with ctrl Ig Treatment with PD-1-blocking Ig
DNA (Plasmid)
Peptide without CpG
adjuvant
Peptide + no CpG
Low dose peptide + CpG
Plasmid
Antigen
stimulation
+ anti-PD-1 Ab
Vaccination
FACS
analysis
(proliferation)
Ex vivo
CFSE staining
of T cells
CD8+ PD-1high
CD8+ PD-1low
CD8+ PD-1low
Figure 3 The responsiveness of CD8
+ T cells is “imprinted”
during the priming phase through PD-1 acquisition. The upper
panel depicts the general methodology: mice were immunized by
various regimens and specific T cells were restimulated ex vivo with
HLA-A*0201-binding human Melan A 26-35 native peptide
(EAAGIGILTV), in the presence of PD-1 blocking antibodies or
control immunoglobulin. Ex vivo T cell proliferation was measured
using a standard CFSE staining assay. The bottom panel depicts a
summary of the results comparing the essential groups: T cells from
Melan A plasmid versus Melan A 26-35 analogue peptide
(ELAGIGILTV) immunized mice. While the epitope-specific T cells
from DNA vaccinated mice had low PD-1 expression and high
proliferative potential persistently, the T cells from peptide
immunized mice had high PD-1 expression and low proliferative
potential; however, their proliferation could be easily restored
through blocking PD-1/PD-1L interaction, speaking to the critical
role of PD-1 in determining the fate of CD8
+ T cells post-priming
(summary of results in refs. [42] and [48]).
Bot et al. Journal of Translational Medicine 2010, 8:132
http://www.translational-medicine.com/content/8/1/132
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a therapeutic setting such as cancer, where endogenous
antigen exposure alone may not be sufficient to initiate
or maintain a clinically relevant immune response.
There may be a more fundamental aspect to these
findings related to the basic immune regulatory pro-
cesses of CD8
+ T cell response in general. The conven-
tional paradigm has been that, upon antigen priming or
stimulation, responding T cells go through an unavoid-
able phase during which they upregulate PD-1 [53].
During the next phase when the antigen exposure
subsides, a minor subset of T cells down-regulate PD-1
and become memory cells, while the larger pool of
effector cells extinguishes through a range of mechan-
isms leading to cellular apoptosis. Conversely, if the
antigen exposure persists or elevates beyond a certain
threshold, the specific T cells would undergo ‘exhaus-
tion’ mediated primarily by PD-1, a quite distinctive
mechanism of immune regulation [54,55]. In the specific
case of HIV, PD-1-induced interleukin-10 production by
monocytes impairs CD4
+ T cell activation, further
amplifying the pathogenesis [55]. Instead of supporting
DNA Priming Boosting
Naïve
T cells
Central Memory T cells
•Enhanced proliferative ability
•Limited effector function
•Narrow migration pattern 
Peripheral Memory / Effector T cells
•Reduced proliferative ability
•High effector function
•Widespread migration pattern
PD-1lo
CD62L+
PD-1hi
CD62L-
A
PD-1lo
CD62L+
Exhausted
T cells
Immune induction / amplification / re-induction, etc. 
Anti-
Infection,
Tumor
B
I
m
m
u
n
i
t
y
Homologous prime-boosting Heterologous prime-boosting
Priming vector => Low PD-1 Priming vector => High PD-1
Highest immunity 
throughout
Vector inducing central memory PD-1lo T cells
Vector inducing peripheral memory PD-1hi T cells
Time
Figure 4 The mechanism of prime-boosting in relation to PD-1-expression and central memory T cells.T h ef l o w c h a r ti nF i g u r e4 A
depicts schematically a proposed mechanism explaining the effectiveness of DNA priming - heterologous boosting in achieving superior
immunity in immune competent organisms. Alternating DNA priming with heterologous boosting (viral vectors, recombinant proteins, peptides,
cells, or cell lysates), achieves alternating production of ‘central-memory’ low PD-1 cells and highly differentiated effector T cells, respectively.
Figure 4B is a temporal perspective on the synergy and differential output of priming and boosting vectors/regimens, respectively. It offers an
explanation to why the exact prime-boost sequence is important based on the differential capability of vectors or regimens to elicit T cells with
different properties such as susceptibility to negative regulatory mechanisms.
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ulation and down-regulation of PD-1), our results sup-
port a ‘branched’ differentiation model for CD8
+ T cells
[56,57]. Accordingly, certain immunization regimens or
immune threats expose lymphatic organs to continu-
ously low levels of antigen and robust co-stimulation
signals, which result in T cells that fail to up-regulate
PD-1 or other co-inhibitory molecules, are less suscepti-
ble to negative regulatory mechanisms, and instead are
in a prolonged state of ‘readiness’ (Figure 6). We can
only speculate that this mechanism of immune regula-
tion, based on a separate PD-1
low T cell branch, evolved
to provide the immune system with an advantage over
highly virulent microbes that easily penetrate the outer
layers of innate immune defense.
Optimization of prime-boost vaccines based on
PD-1 expression and functional avidity of T cells
The body of evidence discussed in this review supports
three major conclusions. First, a heterologous prime-
boost vaccine should ideally encompass a priming regi-
men that results in the induction of specific T cells
co-expressing low levels of inhibitory receptors. Thus,
following a heterologous boost (even within a short time-
frame), these cells would expand and differentiate into
effector cells rather than being subjected to negative reg-
ulatory mechanisms. Secondly, emerging data suggests
that DNA vaccines have the capability to elicit low PD-1
expressing CD8
+ T cells of central-memory phenotype, a
process reproduced by repeat intra-lymph node exposure
to minute levels of antigen in the presence of robust
TLR9 stimulation. Third, this evidence points to a new
dimension of immune homeostasis determined by a tight
and synchronized control of inhibitory molecule expres-
sion by CD8
+ T cells during antigen exposure. This facet
of immune homeostasis would shape - as a function of
antigen exposure and co-stimulation - the delicate bal-
ance between long-lived, readily expandable CD8
+ T cells
and short-lived T cells that are subject to exhaustion or
other negative regulatory mechanisms, in a manner fit-
ting the immunological threat.
Key prerequisites for an effective immune response-to
control disseminated tumors for example-are not only
the sheer numbers of tumor-associated antigen (TAA)-
specific T cells but their quality or capability to recognize
and eradicate cancerous cells. The latter depends on the
functional avidity of the T cells [58] as well as their poly-
functionality [59] in an environment plagued by immune
evasion mechanisms [60]. An interesting fact is that the
induction of high magnitude immunity, generally requir-
ing exposure to significant antigen doses, may result in a
lower proportion of high avidity T cells [61,62]. This is
quite important since tumor cells as well as chronically
infected cells may display significantly reduced amounts
of antigen which are ‘invisible’ to vaccine-specific T cells
displaying low functional avidity, yet readily quantifiable
with current immune monitoring techniques [63].
The interplay between antigen exposure and co-
stimulation, with relevance to the acquisition of PD-1
and preferential induction of high avidity T cells, is
represented in Figure 7. Altogether, this model lays
Naïve phenotype
Activated, central
memory / reduced 
effector phenotype
Activated, peripheral
memory / enhanced 
effector phenotype
Excessively activated, 
anergic / exhausted 
phenotype
Epitope-specific T cells
Vector yielding
PD-1lo central memory 
cells
Vector yielding
PD-1hi peripheral memory 
/ effector cells
Figure 5 Schematic representation of the kinetics of various
subsets of T cells within secondary lymphoid organs. This is a
complementary perspective to that in Figure 4B, providing a
rationale to why a specific sequence of priming and boosting is
important to generating an elevated immune response.
Exhausted T cells
Memory T cells
Low PD-1 High PD-1
Antigen
Conventional model
Sequential up-regulation / down-regulation of PD-1
Exhausted T cells
Memory T cells
Antigen
Low PD-1
Low PD-1
Activated / Effector 
T cells
Naïve 
T cells
High PD-1
•Antigen exposure leads invariably to transient PD-1 
up-regulation
•Subsequent loss of PD-1 is governed by residual 
antigen exposure and other factors 
An alternate, branched model
Differential PD-1 acquisition during priming
High PD-1
Low PD-1
High PD-1
Activated,
Effector,
Memory
T cells
Low PD-1
Naïve 
T cells
•Limited antigen exposure, with potent co-stimulation 
could lead to T cells that retain low PD-1 expression
through various stages: recently activated, effector 
and memory cells 
Antigen
Figure 6 Another dimension to the immune regulation of CD8
+
T cells based on PD-1 expression. The lack of PD-1 up-regulation
during priming may define a separate differentiation lineage. A
current model (left side) depicts activation and differentiation of T
cells, in relation to PD-1 expression, as a sequential upregulation
and downregulation of PD-1, respectively. In this model, activated T
cells unavoidably go through a stage in which they are sensitive to
PD-1/PD-1L dependent negative regulatory mechanisms. Conversely,
in the model depicted on the right side, the acquisition of PD-1
during T cell priming could be limited - depending on the priming
regimen - thus yielding T cells that are not as susceptible to
negative regulatory mechanisms associated with continuous or
repeated antigen exposure. Thus, based on this model - and
supported by recent evidence (42, 48) - immediate boosting would
yield substantially higher immunity as opposed to immune
‘exhaustion’. This enables the development of shortened
immunization regimens utilizing a heterologous prime-boost
strategy.
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prime-boost vaccines and potentially optimizing homo-
logous prime-boost regimens, applicable to difficult
and unmet indications such as cancer and chronic
viral infections. The core principle of this paradigm is
the selection and optimization of the priming vector or
regimen, to achieve induction of specific T cells that
meet the following three criteria:
1) have low expression of co-inhibitory receptors
(PD-1);
2) display a central memory phenotype;
3) have a high TCR functional avidity.
This new paradigm assumes that the selection of vec-
tors is such that it would not result in a deleterious
anti-vector immunity. The priming strategy could then
be matched with heterologous vectors that expand and/
or differentiate the primed cells to therapeutically useful
effector T cells or, alternatively, with homologous boost-
ing leading to much higher antigen exposure than
during priming. Notably, the latter, which could be a
less expensive strategy since it relies only on one vector,
is supported by the observation that exposure to gradu-
ally higher levels of antigen (starting from minute
amounts) over a fairly short interval of just a few days
achieved an unexpectedly robust immune response [64],
usually only attainable by live virus infection or hetero-
logous prime-boost vaccination. A similar principle
could be applied to homologous prime-boost regimens
encompassing naked DNA as primer followed by elec-
troporated DNA as a boosting agent [65]. Effective
priming may also be achievable through intradermal
delivery of DNA as shown in a model of human skin
tattooing [66].
In light of the scarcity of antigen-specific immune
interventions that achieve clear-cut therapeutic benefits
in cancer and chronic infections, there is clearly a need
for advanced vaccine approaches that undergo rigorous
testing and afford objective, quantifiable clinical
responses. The paradigm outlined in this review shifts
the focus from the overarching objective of inducing high
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Figure 7 Co-regulation of PD-1 acquisition and functional avidity of T cells during immune priming. A and B show schematically the key
parameters controlling two complementary features of T cells resulting from immune priming: PD-1 expression (A) and the functional avidity (B).
Effective priming warrants optimal, balanced exposure to TCR-dependent and independent stimuli ("green zone”) resulting in T cells with a
desired effector profile upon boosting. Please note the inverse relationship between functional avidity and the amount of antigen. The table
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Page 8 of 11numbers of vaccine-specific lymphocytes to that of gen-
erating highly efficacious T cells that are potent in
adverse environments brought about by continuous anti-
gen exposure or non-antigen related immune inhibitory
mechanisms. Furthermore, these observations warrant a
revision of current immune monitoring approaches in an
effort to more accurately measure, predict and optimize
the efficacy of active immunotherapies.
Conclusions
Mounting evidence supports a different model defining
the mechanisms of heterologous prime-boost immuniza-
tion at the epitope level. In summary, effective priming
necessitates low PD-1-expressing central memory
T cells and boosting results in their expansion and con-
version to effector T cells equipped with broad migra-
tory and functional capabilities. This mechanism is most
likely linked to a new dimension of immune homeosta-
sis with a possible role in ensuring the ‘response-readi-
ness’ of CD8
+ T cells, depending on the nature and
magnitude of the immunological threat. Finally, this
paradigm suggests a series of valuable criteria to guide
the design of new immunization regimens.
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